what is a glp-1 antagonist Frontiers A Closer Look at the
Description
doi:10.1016/S0140-6736(19)31271-1 13
Ann Transl Med 10(3):152 Yang CY et al (2021) Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
Compounded products are not approved or verified by the FDA for safety, effectiveness, or quality
The weight loss advantage of retatrutide over tirzepatide appears to be approximately 6 percentage points at the highest doses, a clinically meaningful difference
